ARTELO BIOSCIENCES, INC. 8-K

What Happened

• Artelo Biosciences, Inc. (ARTL) filed an 8-K reporting it gave notice on May 11, 2026 to terminate its At-The-Market Offering Agreement with R.F. Lafferty & Co., Inc.; the termination becomes effective May 18, 2026. The Sales Agreement was originally dated July 18, 2025 and allowed the company to sell up to $6,500,000 of common stock through R.F. Lafferty.

Key Details

• Sales Agreement date: July 18, 2025; termination notice given May 11, 2026; effective May 18, 2026.
• Maximum aggregate offering under the program: $6,500,000.
• Shares sold through the program through May 11, 2026: 50,858 shares, generating gross proceeds of $451,526.95.
• Agent under the program: R.F. Lafferty & Co., Inc.

Why It Matters

• Terminating the at-the-market (ATM) sales agreement removes one ready channel Artelo had to raise equity capital by selling shares into the market through R.F. Lafferty.
• To investors, the filing shows the company used only a small portion of the $6.5M capacity (about $451.5K raised), and no replacement financing arrangement or alternative offering was disclosed in this 8-K.
• This is a material change in the company’s available financing tools; shareholders should watch future filings for any new equity programs or other financing announcements.